by Truveta staff | Feb 4, 2025 | Data
The start of a new year can be a time for fresh beginnings and new resolutions. Yet for many, it also brings a renewed struggle with anxiety and depression. The cold, dark days of winter, combined with post-holiday stress and lingering financial pressures, can make...
by Truveta staff | Jan 9, 2025 | Data
In the world of medical research, data drives discovery. But until recently, nearly 80% of data relevant to research has been hidden in clinical notes. These notes include detailed observations, symptoms, and treatment plans that are absent from the structured data...
by Truveta staff | Dec 10, 2024 | Data
“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity Health Electronic health record (EHR) data is rapidly changing how life sciences,...
by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
by Truveta staff | Oct 10, 2024 | Data
The US market size for joint replacement is projected to balloon to nearly $38 billion by 2030, nearly doubling its 2022 value. The combination of an aging population, increasing rates of osteoarthritis and obesity, along with advancing technology, are all...